Gilead teams up with Terray for AI-powered drug discovery, leveraging Terray’s tNova platform to accelerate the development ...

The Breakout clinical trial enrolled 16 patients with type 2 diabetic nephropathy, with eight patients completing the full ...

Founded by a team of scientists and healthcare specialists in 2021, Nintx harnesses compounds from Brazil’s world-famous ...

The pharmaceutical business unit of the German giant Körber has snapped up the compatriot label and leaflet supplier Wilhelm Bähren GmbH & Co as the pharmaceutical packaging market is set to double in ...

Investment in radiopharmaceuticals is ramping up as big pharma shows a growing appetite for this promising drug modality. Radiopharmaceuticals see radioactive isotopes being delivered into a target, ...

Shortly after acquiring a manufacturing site in Wisconsin, Eli Lilly intends to expand it to boost its production of injectable products, including diabetes and obesity drugs Mounjaro and Zepbound.

The potential $2.9 billion deal stands the New Jersey company in good stead after recent disappointing results in its ALS program. PTC Therapeutics announced this week that it has made a deal with ...

The acquisition of Nimble Therapeutics will grant AbbVie access to a pipeline of oral peptide drugs for the treatment of immune diseases including psoriasis and inflammatory bowel disease AbbVie and ...

Pharma company, AbbVie, reports that its D1/D5 partial agonist, tavapadon, has met the primary and secondary endpoints in a pivotal Phase 3 trial. The trial, called TEMPO-2, evaluated the ...